

Interview Summary	Application No.	Applicant(s)
	10/582,385	SANTINI ET AL.
	Examiner MELISSA S. MERCIER	Art Unit 1615

All participants (applicant, applicant's representative, PTO personnel):

(1) MELISSA S. MERCIER.

(3) Mark Quill (attorney of record)

(2) Carlos Azpuru.

(4) Antonio Machado (inventor)

Date of Interview: 11-10-09.

Type: a) Telephonic b) Video Conference
c) Personal [copy given to: 1) applicant 2) applicant's representative]

Exhibit shown or demonstration conducted: d) Yes e) No.
If Yes, brief description: Slide show.

Claim(s) discussed: newly submitted claims 104-109

Identification of prior art discussed: Mr. A. Baojia (US Patent 5,698,582)

Agreement with respect to the claims f) was reached. g) was not reached. h) N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: _____.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN A NON-EXTENDABLE PERIOD OF THE LONGER OF ONE MONTH OR THIRTY DAYS FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

Mr. Machado presented a slide show regarding the background of particle stability comparing alkali metal, and acid conditions and their ability to be formulated in pharmaceutical formulations.

Mr. Quill was requested to provide written support for numerical terms within the new claims, such as "lower than 0.12% w/w", "water content"; "amorphous"; "11-100mg/ml"; "free of ethanol"; addition of (ii) steps into the specification.

all attached.

Mark Quill

Mr. MacEachern further discussed, within the slideshow, the licensing of Bastaft (US Patent 5,698,582); the pH of the composition is not the underlying cause of the degradation. Alcohols, water & alkalinity all contribute to the degradation of the active agents.

Mr. Null was requested to provide a copy of the presented slide show in the interview summary

mm
11-09

applicant is requested to clarify the criticality of the microbes discussed in the slideshow.